Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel in Previously Treated Advanced Melanoma
NCT07288203Phase 2Active, not recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 4
01
Overview
A Phase 2 trial of lifileucel in melanoma, sponsored by Iovance Biotherapeutics. Started Nov 2025; status: active, not recruiting.
02
Drugs
lifileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07288203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288203.